📰 Mark Litton News
Mark Litton News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Litton. Real-time updates on events, politics, business and more.
February 8, 2024
As CD 92.9 FM's final hours broadcasting as a terrestrial radio station ticked down, one of Ohio's U.S. senators tried to intervene before it lost access to the airwaves.
January 26, 2024
View a previous report in the video player above. COLUMBUS, Ohio (WCMH) — A document filed with the Federal Communications Commission sheds light on what may happen when a Columbus alternative radio station is scheduled to go off the air at the end of January. ICS Communications — one of three parties in failed negotiations […]
January 8, 2024
Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease and expects topline data in second half of 2024 Plans to...
January 3, 2024
03.01.2024 - Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of fosgonimeton Potential first-in-class approach ... Seite 1
January 3, 2024
Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of...
December 12, 2023
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...
November 9, 2023
Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candidates targeting the...
May 22, 2023
Veteran biopharmaceutical executive brings over 30 years of financial, corporate strategy, transactional and business development experienceBOTHELL, Wash., May 22, 2023 -- Athira Pharma,... | May 22, 2023
May 11, 2023
Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term... | May 11, 2023
January 31, 2023
BOTHELL, Wash., Jan. 31, 2023 -- Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration,... | January 31, 2023